Dr. Ash Bahl

Head of R&D at Carrick Therapeutics

Dr. Bahl has 25 years of international Pharmaceutical experience working to deliver innovation via drug development projects in the US, Japan, and Europe. His previous roles were with Eli Lilly (2011-2015 as Vice President of External Innovation and Venture partnering), AstraZeneca (1994-2011 Vice President Head of R&D New Opportunities) and Glaxo (1990-1994 Research Scientist).

Dr. Bahl did his first degree in Pharmacy at Kings College London, trained as a pharmacist at John Radcliffe Hospital Oxford and then a PhD in Immunopharmacology at University College London (UCL). Dr. Bahl has delivered over 10 compounds into clinical development from his leadership of drug discovery projects. In his role as Vice President Head of R&D within New Opportunities at AstraZeneca (2007-2011) he ran and initiated R&D collaborations with Alcon in Ophthalmology, Galderma in dermatology and a pioneering collaboration with the Medical Research Council in drug repositioning. In his role within Eli Lilly he helped to pioneer the NIH/NCATs new therapeutic indications pilot and developed Lilly’s R&D input into venture funding. In collaboration with the Chorus Unit at Lilly and Lilly’s Venture funds in the UK, USA and Europe Dr. Bahl was instrumental in the creation of several new companies during his time at Lilly. Some of these companies pioneered new therapeutic areas for Eli Lilly e.g Hearing loss disorders and Immuno oncology.